Highlights:

• Group operating profit increased 6.7% to A$813.5 million, supported by growth across Medibank’s insurance and health services operations.
• Underlying NPAT rose 2.9% to A$636.8 million, while statutory NPAT climbed 27.5% to A$638.7 million.
• Medibank Health segment profit surged 31.3% to A$100.7 million, strengthening the group’s diversification strategy.

Solid FY26 Financial Performance

Medibank Private Limited (ASX: MPL) delivered higher earnings for the 12 months ended 30 June 2026, with its full-year results announced on 20 August 2026. The health insurer reported group operating profit of AU$813.5 million, representing growth of 6.7% over the previous financial year. Underlying net profit after tax reached AU$636.8 million, up 2.9%, while statutory NPAT increased 27.5% to AU$638.7 million. Group revenue also expanded by 5.9% to AU$9.12 billion, reflecting continued growth across the company's key operating divisions.

Health Insurance Business Maintains Stability

Medibank's core Health Insurance business continued to deliver steady earnings despite heightened competition. The company added approximately 22,100 resident policyholders, increasing its resident customer base by 1.1% to 2.03 million. Health Insurance operating profit increased 3.8% to AU$769.8 million, supported by premium revenue of AU$8.59 billion. The gross margin remained at 17.0%, while the management expense ratio was unchanged at 8.0%. The Medibank brand recorded improved customer growth, while budget-focused ahm continued to expand. However, the lapse rate increased to 10.5%, and non-resident policy units declined amid softer conditions within the international student market.

Medibank Health Emerges as a Key Growth Engine

The strongest growth came from the Medibank Health division, where segment profit climbed 31.3% to AU$100.7 million. Revenue from the division rose 30.8% to AU$634.8 million, benefiting from organic expansion and the contribution from Better Medical. Medibank acquired the primary healthcare group for AU$163.5 million, with the business contributing for six months during FY26. Community and acute care revenue also grew strongly, while home health admissions increased by 13.7%.

Investment Income and Customer Benefits

Net investment income declined 13.9% to AU$178.9 million, partly reflecting lower interest rates. Meanwhile, residual costs associated with the cybercrime incident reduced to AU$34.9 million. Customers received approximately AU$49 million in Live Better rewards, while Members' Choice networks generated around AU$243 million in customer savings.

Dividend and FY27 Outlook

Medibank declared a fully franked final dividend of 10.9 cents per share, taking the FY26 dividend to 19.2 cents per share, up 6.7%. Looking ahead, management expects approximately 25% growth in Medibank Health segment profit in FY27, although the company also expects the benefit from a AU$74.8 million non-recurring claims item to unwind.Note- All data presented is based on information available at the time of writing.Disclaimer for Kapitales ResearchThe materials provided by Kapitales Research, including articles, news, data, reports, opinions, images, charts, and videos ("Content"), are intended for personal, non-commercial use only. The primary goal of this Content is to educate and inform readers. This Content is not meant to offer financial advice, nor does it include any recommendation or opinion that should be relied upon for making financial decisions. Certain Content on this platform may be sponsored or unsponsored, but it does not serve as a solicitation or endorsement to buy, sell, or hold any securities, nor does it encourage any specific investment activities. Kapitales Research is not authorized to provide investment advice, and we strongly advise users to seek guidance from a qualified financial professional, such as a financial advisor or stockbroker, before making any investment choices. Kapitales Research disclaims all liability for any direct, indirect, incidental, or consequential damages arising from the use of the Content, which is provided without any warranties. The opinions expressed by contributors or guests are their own and do not necessarily reflect the views of Kapitales Research. Media such as images or music used on this platform are either owned by Kapitales Research, sourced through paid subscriptions, or believed to be in the public domain. We have made reasonable efforts to credit sources where appropriate. Kapitales Research does not claim ownership of any third-party media unless explicitly stated otherwise. 

Customer Notice:

Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.

Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com.au